Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353997 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29378420 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL30191581 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29401430 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL178787 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL31675022 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29792126 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL118051 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3TLR2MDM2 | |
| Water SCHEMBL21809391 | 0.99 | MDM4 (0.59) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL22636280 | 0.93 | MDM4 (0.59) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679495-B | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-113717170-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210330651-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC | 2021-10-28 | — | — | US | disclosed |
| CN-109311870-B | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11065234-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-11065233-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| CN-112745316-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112679495-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-04-20 | — | — | CN | disclosed |
| US-10959989-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200261428-A1 | ESTROGEN RECEPTOR MODULATORS | KALYRA PHARMACEUTICALS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065233-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRG | MDM4 3715/4885TP53 259/4885CASP3 4155/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MDM4 934/4885TP53 3426/4885CASP3 760/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | MDM4 4381/4885TP53 3992/4885CASP3 513/4885 |
| US-20200261428-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | MDM4 3715/4885TP53 259/4885CASP3 4155/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MDM4 963/4885TP53 81/4885CASP3 3087/4885 |
| US-10959989-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRG | MDM4 3715/4885TP53 259/4885CASP3 4155/4885 |
| US-20210330651-A1 | ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESRRG | MDM4 3715/4885TP53 259/4885CASP3 4155/4885 |
| US-11065234-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRG | MDM4 3715/4885TP53 259/4885CASP3 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.